Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer

Journal of Surgical Oncology

Volumn 105, Issue 1, 2012, Pages 31-37

  Li, Ping ^a   Qian, Jianxin ^a   Yu, Guanzhen ^a   Chen, Ying ^b   Liu, Ke ^a   Li, Jie ^a   Wang, Jiejun ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Gastric cancer; LOH; Prognosis; SPARCL1

Indexed keywords

GLYCOPROTEIN; MESSENGER RNA; SPARC LIKE PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER SURVIVAL; CANCER TISSUE; CHINESE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH MUCOSA; TISSUE MICROARRAY; WESTERN BLOTTING;

ADENOCARCINOMA; CALCIUM-BINDING PROTEINS; CARCINOMA, SIGNET RING CELL; CASE-CONTROL STUDIES; DOWN-REGULATION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH; STOMACH NEOPLASMS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 83555176229     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22025     Document Type: Article

References (29)

1. Milne AN, Carneiro F, O'Morain C, et al.: Nature meets nurture: Molecular genetics of gastric cancer. Hum Genet 2009; 126: 615-628.
2. Zhao ZS, Wang YY, Chu YQ,: SPARC is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 2010; 16: 260-268.
3. Claeskens A, Ongenae N, Neefs JM, et al.: Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation. Br J Cancer 2000; 82: 1123-1130. (Pubitemid 30128867)
4. Esposito I, Kayed H, Keleg S, et al.: Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia 2007; 9: 8-17. (Pubitemid 46203930)
5. St Croix B, Rago C, Velculescu V,: Genes expressed in human tumor endothelium. Science 2000; 289: 1197-1202. (Pubitemid 30650733)
6. Hambrock HO, Nitsche DP, Hansen U, et al.: SC1/hevin. An extracellular calcium-modulated protein that binds collagen I. J Biol Chem 2003; 278: 11351-11358. (Pubitemid 36792693)
7. Sullivan MM, Sage EH,: Hevin/SC1, a matricellular glycoprotein and potential tumor-suppressor of the SPARC/BM-40/Osteonectin family. Int J Biochem Cell Biol 2004; 36: 991-996. (Pubitemid 38501551)
8. Sullivan MM, Puolakkainen PA, Barker TH, et al.: Altered tissue repair in hevin-null mice: Inhibition of fibroblast migration by a matricellular SPARC homolog. Wound Repair Regen 2008; 16: 310-319. (Pubitemid 351342139)
9. Girard JP, Springer TA,: Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity 1995; 2: 113-123.
10. Nelson PS, Plymate SR, Wang K, et al.: Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma. Cancer Res 1998; 58: 232-236. (Pubitemid 28047060)
11. Bendik I, Schraml P, Ludwig CU,: Characterization of MAST9/Hevin, a SPARC-like protein, that is down-regulated in non-small cell lung cancer. Cancer Res 1998; 58: 626-629. (Pubitemid 28099469)
12. Brekken RA, Sullivan MM, Workman G, et al.: Expression and characterization of murine hevin (SC1), a member of the SPARC family of matricellular proteins. J Histochem Cytochem 2004; 52: 735-748. (Pubitemid 38703128)
13. Lau CP, Poon RT, Cheung ST, et al.: SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. J Pathol 2006; 210: 459-468. (Pubitemid 44830606)
14. Scalabrini D, Fenoglio C, Scarpini E, et al.: Candidate gene analysis of SPARCL1 gene in patients with multiple sclerosis. Neurosci Lett 2007; 425: 173-176. (Pubitemid 47418363)
15. Mencalha AL, Levinsphul A, Deterling LC, et al.: SPARC-like1 mRNA is overexpressed in human uterine leiomyoma. Mol Med Report 2008; 1: 571-574.
16. Iacobuzio-Donahue CA, Ryu B, Hruban RH, et al.: Exploring the host desmoplastic response to pancreatic carcinoma: Gene expression of stromal and neoplastic cells at the site of primary invasion. Am J Pathol 2002; 160: 91-99. (Pubitemid 34052270)
17. Barker TH, Framson P, Puolakkainen PA, et al.: Matricellular homologs in the foreign body response: Hevin suppresses inflammation, but hevin and SPARC together diminish angiogenesis. Am J Pathol 2005; 166: 923-933. (Pubitemid 40315648)
18. Yu G, Wang J, Chen Y, et al.: Tissue microarray analysis reveals strong clinical evidence for a close association between loss of annexin A1 expression and nodal metastasis in gastric cancer. Clin Exp Metastasis 2008; 25: 695-702.
19. Yu G, Wang J, Chen Y, et al.: Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res 2009; 15: 1821-1829.
20. Liu K, Wang G, Ding H, et al.: Downregulation of metastasis suppressor 1(MTSS1) is associated with nodal metastasis and poor outcome in Chinese patients with gastric cancer. BMC Cancer 2010; 10: 428.
21. Sakashita K, Mimori K, Tanaka F, et al.: Clinical significance of loss of Fhl1 expression in human gastric cancer. Ann Surg Oncol 2008; 15: 2293-2300.
22. Cheung TH, Lo KW, Yim SF, et al.: Clinicopathologic significance of loss of heterozygosity on chromosome 1 in cervical cancer. Gynecol Oncol 2005; 96: 510-515. (Pubitemid 40127157)
23. Ploussard G, Dubosq F, Soliman H, et al.: Prognostic value of loss of heterozygosity at chromosome 9p in non-muscle-invasive bladder cancer. Urology 2010; 76: e513-e518.
24. Cai T, Nesi G, Dal Canto M, et al.: Prognostic role of loss of heterozygosity on chromosome 18 in patients with low-risk nonmuscle-invasive bladder cancer: Results from a prospective study. J Surg Res 2010; 161: 89-94.
25. Isler SG, Schenk S, Bendik I, et al.: Genomic organization and chromosomal mapping of SPARC-like 1, a gene down regulated in cancers. Int J Oncol 2001; 18: 521-526.
26. Lerebours F, Olschwang S, Thuille B, et al.: Fine deletion mapping of chromosome 8p in non-small-cell lung carcinoma. Int J Cancer 1999; 81: 854-858. (Pubitemid 29249967)
27. Rumpel CA, Powell SM, CA M,: Mapping of genetic deletions on the long arm of chromosome 4 in human esophageal adenocarcinomas. Am J Pathol 1999; 154: 1329-1334. (Pubitemid 29226427)
28. Shivapurkar N, Virmani AK, Wistuba II, et al.: Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. Clin Cancer Res 1999; 5: 17-23. (Pubitemid 29045173)
29. Shivapurkar N, Sood S, Wistuba II, et al.: Multiple regions of chromosome 4 demonstrating allelic losses in breast carcinomas. Cancer Res 1999; 59: 3576-3580. (Pubitemid 29381855)